Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) ...

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...

Novel conditioning regimen improves survival and engraftment in sickle cell transplant patients with low graft versus host ...

A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...

Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf ...

FDA cleared once-daily ruxolitinib XR for MF, HU-refractory/intolerant PV, and steroid-refractory acute/chronic GVHD after ...

Disease-free survival of 96% with no severe GVHD in acute leukemia, other blood cancers ...

A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant. A Phase II clinical trial of patients ...

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) ...

Amandeep Salhotra, MD, of City of Hope National Medical Center in Duarte, California, explores the safety and tolerability of ...

Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...

If you’re living with chronic graft-versus-host disease (GVHD) — or supporting someone who is — you know this condition rarely affects just one part of the body. When symptoms involve the skin, joints ...